MX2019013528A - Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia). - Google Patents
Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia).Info
- Publication number
- MX2019013528A MX2019013528A MX2019013528A MX2019013528A MX2019013528A MX 2019013528 A MX2019013528 A MX 2019013528A MX 2019013528 A MX2019013528 A MX 2019013528A MX 2019013528 A MX2019013528 A MX 2019013528A MX 2019013528 A MX2019013528 A MX 2019013528A
- Authority
- MX
- Mexico
- Prior art keywords
- sgsh
- variants
- iiia
- sulfamidase
- vectors
- Prior art date
Links
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 title abstract 10
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 title abstract 2
- 208000025816 Sanfilippo syndrome type A Diseases 0.000 title 2
- 208000012226 mucopolysaccharidosis type IIIA Diseases 0.000 title 2
- 239000000203 mixture Substances 0.000 title 1
- 208000005340 mucopolysaccharidosis III Diseases 0.000 title 1
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 title 1
- 208000036710 mucopolysaccharidosis type 3A Diseases 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 101000651201 Homo sapiens N-sulphoglucosamine sulphohydrolase Proteins 0.000 abstract 7
- 241000124008 Mammalia Species 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762505423P | 2017-05-12 | 2017-05-12 | |
| PCT/US2018/032454 WO2018209317A1 (en) | 2017-05-12 | 2018-05-11 | Sulfamidase (sgsh) variants, vectors, compositions and methods and uses for treating mucopolysaccharidosis type iiia (mps iiia) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013528A true MX2019013528A (es) | 2020-07-14 |
Family
ID=64104969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013528A MX2019013528A (es) | 2017-05-12 | 2018-05-11 | Variantes de sulfamidasa (sgsh) y vectores, composiciones, metodos y usos para tratar la mucopolisacaridosis tipo iiia (mps iiia). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12221635B2 (enExample) |
| EP (1) | EP3622060A4 (enExample) |
| JP (1) | JP7196099B2 (enExample) |
| CN (1) | CN110809626A (enExample) |
| AU (1) | AU2018265869C1 (enExample) |
| BR (1) | BR112019023869A2 (enExample) |
| CA (1) | CA3061925A1 (enExample) |
| MX (1) | MX2019013528A (enExample) |
| RU (1) | RU2019140862A (enExample) |
| WO (1) | WO2018209317A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108728495A (zh) * | 2018-05-31 | 2018-11-02 | 深圳市免疫基因治疗研究院 | 一种Sanfilippo A综合症慢病毒载体、慢病毒及其制备方法和应用 |
| ES3035673T3 (en) * | 2018-12-20 | 2025-09-08 | Esteve Pharmaceuticals Sa | Recombinant vectors for the long term treatment of mucchopolysacharidosis |
| WO2021011841A1 (en) * | 2019-07-18 | 2021-01-21 | Lysogene | Compositions and methods for the treatment of sanfilippo disease and other disorders |
| CN115023242B (zh) | 2019-11-22 | 2025-03-14 | 费城儿童医院 | 腺相关病毒载体变体 |
| KR20220153021A (ko) * | 2020-03-11 | 2022-11-17 | 리모터 테라퓨틱스, 인코포레이티드 | 중추신경계를 통한 단백질을 확산시키기 위한 방법 및 재료 |
| CN111718947B (zh) * | 2020-06-18 | 2022-08-23 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途 |
| AU2022388800A1 (en) * | 2021-11-12 | 2024-06-27 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of mucopolysaccharidosis iiia |
| US20250034533A1 (en) * | 2021-11-12 | 2025-01-30 | Amicus Therapeutics, Inc. | Compositions And Methods For Treating Mucopolysaccharidosis IIIA |
| WO2023204202A1 (ja) * | 2022-04-19 | 2023-10-26 | Ｊｃｒファーマ株式会社 | マンノース－６－リン酸の数を減少させた糖蛋白質 |
| CN115029360B (zh) * | 2022-05-30 | 2024-08-02 | 上海勉亦生物科技有限公司 | 用于治疗粘多糖贮积症iiia型的转基因表达盒 |
| CN120379648A (zh) * | 2022-12-23 | 2025-07-25 | 株式会社绿十字 | 具有改善的稳定性的包含乙酰肝素n-硫酸酯酶的药物组合物 |
| WO2026162810A1 (en) * | 2025-02-03 | 2026-08-06 | Institut National de la Santé et de la Recherche Médicale | Methods for the intravenous treatment of sanfilippo syndrome type iiia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863782A (en) * | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| EP2550359B1 (en) * | 2010-03-23 | 2017-08-09 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| EP2394667A1 (en) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| ES2745470T3 (es) * | 2011-03-31 | 2020-03-02 | Univ Iowa Res Found | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv |
| EP3166626B1 (en) * | 2014-07-11 | 2021-04-28 | Biostrategies LC | Materials and methods for treating disorders associated with sulfatase enzymes |
-
2018
- 2018-05-11 MX MX2019013528A patent/MX2019013528A/es unknown
- 2018-05-11 US US16/611,458 patent/US12221635B2/en active Active
- 2018-05-11 AU AU2018265869A patent/AU2018265869C1/en active Active
- 2018-05-11 EP EP18798587.4A patent/EP3622060A4/en active Pending
- 2018-05-11 JP JP2019562293A patent/JP7196099B2/ja active Active
- 2018-05-11 WO PCT/US2018/032454 patent/WO2018209317A1/en not_active Ceased
- 2018-05-11 CN CN201880043043.4A patent/CN110809626A/zh active Pending
- 2018-05-11 CA CA3061925A patent/CA3061925A1/en active Pending
- 2018-05-11 BR BR112019023869-7A patent/BR112019023869A2/pt active Search and Examination
- 2018-05-11 RU RU2019140862A patent/RU2019140862A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018209317A1 (en) | 2018-11-15 |
| AU2018265869C1 (en) | 2025-01-30 |
| CA3061925A1 (en) | 2018-11-15 |
| AU2018265869A1 (en) | 2019-11-21 |
| US20210324354A1 (en) | 2021-10-21 |
| RU2019140862A3 (enExample) | 2021-08-17 |
| JP2020519629A (ja) | 2020-07-02 |
| EP3622060A1 (en) | 2020-03-18 |
| EP3622060A4 (en) | 2021-02-17 |
| BR112019023869A2 (pt) | 2020-06-09 |
| RU2019140862A (ru) | 2021-06-15 |
| JP7196099B2 (ja) | 2022-12-26 |
| CN110809626A (zh) | 2020-02-18 |
| AU2018265869B2 (en) | 2024-10-24 |
| US12221635B2 (en) | 2025-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019023869A2 (pt) | variantes de sulfamidase (sgsh), vetores, composições e métodos e usos para tratar mucopolissacaridose tipo iiia (mps iiia) | |
| EP4219728A3 (en) | Enhanced delivery of viral particles to the striatum and cortex | |
| PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
| MY188987A (en) | Aav vectors for retinal and cns gene therapy | |
| EP4299079A3 (en) | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid | |
| EP4491733A3 (en) | Modulation of aav vector transgene expression | |
| MX2020012816A (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. | |
| HK1207109A1 (en) | Methods and compositions for treating amyloid deposits | |
| MX2017011615A (es) | Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1. | |
| WO2016161124A8 (en) | COMPOSITIONS AND METHODS FOR DECREASING CONVULSIONS | |
| WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
| WO2018160712A8 (en) | Regenerating functional neurons for treatment of neural injury caused by disruption of blood flow | |
| MY195391A (en) | Column-Based Fully Scalable Raav Manufacturing Process | |
| MX2019005266A (es) | Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas. | |
| ZA201701881B (en) | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma | |
| PH12017500098A1 (en) | Suspension compositions of cyclosporin a for subconjunctival and periocular injection | |
| WO2019222314A8 (en) | Raav vectors encoding of lysosomal beta-galactosidase (glb1) and cathepsin a | |
| MX2020007555A (es) | Anticuerpos potenciadores del factor h y usos de los mismos. | |
| WO2018013775A3 (en) | Granulin compositions and uses related thereto | |
| EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
| MX2018011016A (es) | Formulaciones estables para liofilizar particulas terapeuticas. | |
| PH12017501549B1 (en) | Peptides for inhibiting angiogenesis | |
| MX2023008839A (es) | Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales. | |
| MX388998B (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| TN2016000460A1 (en) | Aav vectors for retinal and cns gene therapy. |